MET and breast cancer: For example, miR-30e* promotes invasion of glioma cells by acting on IκBα 26; miR-378* mediates metabolic conversion of breast cancer cells by targeting the PGC-1β/ERRγ pathway 27; miR-29c* inhibits progression of gallbladder cancer by directly targeting CPEB4 and thus inhibiting the MAPK pathway 28, and miR-199a* controls expression of the proto-oncogene MET 29.